Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
Yttrium-90 ibritumomab tiuxetan (Zevalin -IDEC) was approved by the FDA for treatment of patients with relapsed or refractory low-grade follicular or transformed B-cell non-Hodgkin's lymphoma (NHL), including patients with follicular lymphoma refractory to rituximab (Rituxan -Medical Letter 1998; 40:65). Zevalin is the first radioimmunoconjugate to be approved for treatment of cancer....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Ibritumomab Tiuxetan (Zevalin) for Non-Hodgkin's Lymphoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1144
Article Code: 1144c
Date: November 25, 2002
Volume: 44
Pages: 101-102
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1144
Article Code: 1144c
Date: November 25, 2002
Volume: 44
Pages: 101-102
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)